CSPC Pharmaceutical Group Limited Total Assets
CSPC Pharmaceutical Group Limited total assets. Based on the latest financial reports, CSPC Pharmaceutical Group Limited (CVG) holds total assets worth €46.70 Billion EUR (≈ $54.59 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of CSPC Pharmaceutical Group Limited for the company's overall valuation and market capitalisation.
Total Assets of CSPC Pharmaceutical Group Limited (2013–2025)
Total assets of CSPC Pharmaceutical Group Limited from 2013 to 2025. This chart illustrates how CSPC Pharmaceutical Group Limited's total assets have evolved over time, based on quarterly financial data. See today's stock price for CSPC Pharmaceutical Group Limited for real-time trading data and today's change.
CSPC Pharmaceutical Group Limited - Asset Composition Analysis
CSPC Pharmaceutical Group Limited Total Assets Breakdown (December 2025)
CSPC Pharmaceutical Group Limited total assets breakdown as of December 2025. CSPC Pharmaceutical Group Limited's total assets of €46.70 Billion consist of 47.7% current assets and 52.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.0% |
| Accounts Receivable | €4.78 Billion | 10.2% |
| Inventory | €3.09 Billion | 6.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.77 Billion | 5.9% |
| Goodwill | €234.90 Million | 0.5% |
Asset Composition Trend (2013–2025)
This chart illustrates how CSPC Pharmaceutical Group Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is CSPC Pharmaceutical Group Limited's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CSPC Pharmaceutical Group Limited's current assets represent 47.7% of total assets in 2025, a decrease from 52.2% in 2013.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2025, up from 9.7% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 1.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 10.2% of total assets.
CSPC Pharmaceutical Group Limited Competitors by Total Assets
Key competitors of CSPC Pharmaceutical Group Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX116.43 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.18 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
CSPC Pharmaceutical Group Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.19 | 2.27 | 2.53 |
| Quick Ratio | 1.88 | 1.95 | 2.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €12.07 Billion | €12.25 Billion | €9.62 Billion |
CSPC Pharmaceutical Group Limited - Advanced Valuation Insights
This section examines the relationship between CSPC Pharmaceutical Group Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.41 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | €46.70 Billion |
| Market Capitalization | $10.04 Billion USD |
Valuation Analysis
Below Book Valuation: The market values CSPC Pharmaceutical Group Limited's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CSPC Pharmaceutical Group Limited's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CSPC Pharmaceutical Group Limited (2013–2025)
The table below shows the annual total assets of CSPC Pharmaceutical Group Limited from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €46.70 Billion ≈ $54.59 Billion |
+5.20% |
| 2024-12-31 | €44.39 Billion ≈ $51.90 Billion |
-4.09% |
| 2023-12-31 | €46.28 Billion ≈ $54.11 Billion |
+10.80% |
| 2022-12-31 | €41.77 Billion ≈ $48.83 Billion |
+20.23% |
| 2021-12-31 | €34.74 Billion ≈ $40.62 Billion |
+15.53% |
| 2020-12-31 | €30.07 Billion ≈ $35.16 Billion |
+14.26% |
| 2019-12-31 | €26.32 Billion ≈ $30.77 Billion |
+13.58% |
| 2018-12-31 | €23.17 Billion ≈ $27.09 Billion |
+28.72% |
| 2017-12-31 | €18.00 Billion ≈ $21.05 Billion |
+36.20% |
| 2016-12-31 | €13.22 Billion ≈ $15.45 Billion |
-2.39% |
| 2015-12-31 | €13.54 Billion ≈ $15.83 Billion |
+8.31% |
| 2014-12-31 | €12.50 Billion ≈ $14.62 Billion |
+2.46% |
| 2013-12-31 | €12.20 Billion ≈ $14.26 Billion |
-- |
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more